Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Neutralization of HIV type 1 by alloimmune sera derived from polytransfused patients.

AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):533-43. Unique Identifier : AIDSLINE MED/99236719
Spruth M; Stoiber H; Kacani L; Schonitzer D; Dierich MP; Institut fur Hygiene, Leopold-Franzens-Universitat Innsbruck; and Ludwig-Boltzmann Institut fur AIDS-Forschung, Innsbruck,; Austria.

Abstract: Antibodies (Abs) against HLA and other cell surface molecules, which HIV-1 acquires during the budding process at the host cell surface, neutralize HIV-1 in vitro. Macaques were protected against infection by SIV grown in human cells after xenoimmunization with human MHC molecules. Besides the immune responses arising against xenogeneic antigens, the highly polymorphic character of the HLA antigens enables the induction of alloresponses after exposure to allogeneic HLA molecules. Since polytransfused (PT) patients develop alloresponses, including humoral anti-HLA responses, we assumed that sera derived from PT patients may neutralize HIV-1. In a model system two PT sera out of a panel of 12 PT and 6 normal control sera neutralized HIV IIIB in vitro. Neutralizing activity of the PT sera was comparable to the efficacy of anti-HIV sera. The neutralizing capacity coincided with strong IgG reactivity against (HIV-infected) cell lines, which were used for virus production, and recognition of cell-free viral particles. Active human complement enhanced HIV neutralization mediated by the sera. Our results suggest an IgG-mediated neutralization based on recognition of allogeneic HLA molecules expressed on the viral surface. A vaccination strategy based on alloimmunization appears conceivable and requires further investigation.

Keywords: JOURNAL ARTICLE *Blood Transfusion Complement/IMMUNOLOGY Complement Activation/IMMUNOLOGY Hela Cells Human HIV-1/*IMMUNOLOGY *Immune Sera Isoantibodies/*IMMUNOLOGY Neutralization Tests Support, Non-U.S. Gov't Tumor Cells, Cultured U937 Cells Virion/IMMUNOLOGY
990930
A9991331

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .